Anatomical and Functional Outcomes of Macular Edema Complicating Retinal Vein Occlusions (RVO) Treated with Intravitreal Anti-VEGF Injections at Bouaké University Hospital
Objective: To describe the anatomical and functional outcomes of macular edema complicating Retinal Vein Occlusion (RVO) in patients treated with intravitreal anti-VEGF injections, with the aim of improving its management. Patients and methods: This was a prospective descriptive study conducted in the Department of Ophthalmology of Bouaké University Hospital from 18/08/2023 to 18/08/2025, over a period of 24 months. All patients with an accessible fundus examination, in whom RVO complicated by macular edema was confirmed by OCT and who received three intravitreal anti-VEGF injections (aflibercept), were included. Patients in whom macular edema could not be confirmed by OCT and those who did not receive the three intravitreal anti-VEGF injections were excluded. The parameters studied were epidemiological (age, sex, occupation, risk factors), clinical (distance visual acuity, intraocular pressure, RVO location, fundus lesions before and after anti-VEGF injections) and para -clinical (central foveal thickness before and after anti-VEGF injections). Data entry and analysis were performed using Epi Info version 7.1.3. Word-processing and tables were produced using Microsoft Word. Results: The hospital frequency of macular edema complicating RVO was 30% (n=24). The mean age was 58.41 years, ranging from 31 to 77 years. There was a male predominance of 75% (n=18), with a sex ratio of 3. The most common risk factor was glaucoma, in 50% (n=12) of cases. The right eye was most affected, accounting for 58.33% of cases (n=14). Initial distance visual acuity was ≤1/20 in 83.33% (n=20) of cases. Mean intraocular pressure was 23.33 mmHg, ranging from 18 to 35 mmHg. Central Retinal Vein Occlusion (CRVO) predominated in 50% of cases (n=12), followed by inferior Branch Retinal Vein Occlusion (BRVO) in 41.66% (n=10). Mean central macular thickness was 524.58 µm, ranging from 292 to 1075 µm. After three anti-VEGF injections, clinical signs of RVO and macular edema regressed in 100% of cases (n=24). Distance visual acuity improved to between 1/10 and 3/10 in 91.66% (n=22) of patients and central macular thickness decreased by 291.33 µm, with a mean post-treatment central macular thickness of 233.25 µm. Conclusion: Intravitreal aflibercept injections in the management of macular edema complicating retinal vein occlusions improve the anatomical and functional prognosis of the affected eye.
Authors
- Gosse François Diomandé
- Godé LE
- Yves Ouattara
- Goulé AM
- I.A. Diomandé
- Koffi KAP
- Koffi KF-H
- Bilé PEFK
- Babayeju RLO
- Diabaté Z
- Konan MP
- Ikpo G
Institutions
- Université Alassane Ouattara (CI)
- University Hospital Medical Center at Treichville (CI)
- Centre Hospitalier Universitaire de Cocody (CI)
Publication Details
- Journal
- Journal of Ophthalmology and Advance Research
- Published
- 2026-11-15
- DOI
- https://doi.org/10.46889/joar.2026.7309
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00